Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

153.99 +4.38 (+2.93%)
Streaming Delayed Price Updated: 2:05 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
56 57 Next >
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
Could Eli Lilly Stock Help You Become a Millionaire?
Over the past 10 years, when including its dividend, Eli Lilly's total return has amounted to an incredible 843%. 
Via The Motley Fool
Biogen Names Priya Singhal as Executive Vice President, Head of Development
From Biogen Inc.
Via GlobeNewswire
Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
From Biogen Inc.
Via GlobeNewswire
1 Large-Cap Biotech Stock to Buy for 2023 and Beyond
This company's best asset may be its pipeline. 
Via The Motley Fool
What's Going On With Biogen Stock Today?
Biogen Inc (NASDAQ: BIIB) shares traded higher Thursday morning before pulling back. Reports indicate that the FDA's process for approving Biogen's Alzheimer's drug Aduhelm was filled with... 
Via Benzinga
The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock
Investors are closely watching two key spaces that could spark Lilly stock. 
Via Investor's Business Daily
The Top Three Stocks Analysts Say To Buy
The analysts are rewarding companies that prove they can succeed in the face of headwinds and the most upgraded in Q4 2022 are Netflix, Biogen and Nike. 
Via MarketBeat
Is Biogen's Stock Too Risky to Invest in?
Even at a discount, investors may be taking on a big risk with Biogen. 
Via The Motley Fool
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
1 Green Flag and 1 Red Flag for Biogen
Biogen beat the bear market this year. 
Via The Motley Fool
Is Biogen Stock a Buy Now?
Its revenue now has a plausible path to doubling, but risks remain high. 
Via The Motley Fool
Roche's Follicular Lymphoma Therapy Scores FDA Approval
 
Via Benzinga
3 Nasdaq Stocks That Are Up 25% in 3 Months
Should you jump on the bandwagon and buy these surging stocks? 
Via The Motley Fool
Biogen's Alzheimer's Antibody Might Have A Third Death Associated With
A third death is supposedly linked with Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's antibody, lecanemab. 
Via Benzinga
Has This Top Pharma Company Found Its Next Billion-Dollar Product?
Eli LIlly is looking to make waves in an important therapeutic area. 
Via The Motley Fool
Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer’s Disease
The estimated cost of Alzheimer's disease and related dementia (ADRD) care in 2021 was $355 billion. Investing in the top companies that are making steady progress toward developing a treatment for... 
Via Talk Markets
Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
From Biogen Inc.
Via GlobeNewswire
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years. 
Via InvestorPlace
Buying These Unstoppable Stocks Before 2023 Could Be a Genius Move
These stocks have climbed by double digits this year. 
Via The Motley Fool
Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock
Both stocks are heading for double-digit gains this year. 
Via The Motley Fool
FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)
From Biogen Inc.
Via GlobeNewswire
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
The three companies are changing the pharmaceutical industry. 
Via The Motley Fool
Why 2023 Could Be a Big Year for Biogen
Investors will soon learn if the company's Alzheimer's treatment gets the green light. 
Via The Motley Fool
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Sage Therapeutics, Inc.
Via Business Wire
European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS
From Biogen Inc.
Via GlobeNewswire
Even After This Year’s Melt-Up, Runway Remains for LLY Stock
The market hasn't overreacted with its enthusiasm for LLY stock, as the pharma giant makes progress with a blockbuster drug in the making. 
Via InvestorPlace
Can These 2 Stocks Crush the Market Again in 2023?
Both are riding the wave of major clinical wins 
Via The Motley Fool
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review
The S&P 500 is fighting for its 200-day, a critical level for the uptrend. 
Via Investor's Business Daily
Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate
Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD). 
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.